Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Apogee Therapeutics Inc.

In a report released on April 2, Julian Harrison from BTIG reiterated a Buy rating on Apogee Therapeutics, with a price target of $137.00. The comp...

Apogee Therapeutics (APGE) Receives a Rating Update from a Top Analyst

Guggenheim analyst Seamus Fernandez reiterated a Buy rating on Apogee Therapeutics yesterday and set a price target of $160.00. The company’s share...

Guggenheim Keeps Their Buy Rating on Apogee Therapeutics (APGE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Apogee Therapeutics (APGE) and Theriva Biologics (...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Apogee Therapeutics (APGE) and Theriva Biologics (TOVX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GIL...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Apogee Therapeutics (APGE) and Gilead Sciences (GILD)

Traders seeking the top stock market stories for Monday will find them in the TipRanks daily wrap-up.


Morning News Wrap-Up 3/23/26: Today’s Biggest Stock Market Stories!

Apogee Therapeutics stock gained on Monday alongside strong results from the company’s latest clinical trial.


Why Did Apogee Therapeutics Stock (APGE) Soar Today?

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beta Bionics, Inc. (BBNX), Apogee Therapeutics (APGE...

Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (BBNX), Apogee Therapeutics (APGE) and Solid Biosciences (SLDB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Apogee Therapeutics (APGE – Research Report), Wave L...

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Chugai Pharmaceutical Co (CHGCF – Research Report), ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	APGE	$82.98	-0.36%	567.72K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	APGE	$82.98	-0.4%	567.72K
3
4
5
6

APGE

APGE

Get Apogee Therapeutics Inc. Data in Excel

Get Apogee Therapeutics Inc. Data in Excel